Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …

Guidelines are mainly based on evidence of well-designed randomized controlled trials
(RCTs), but there are limitations to the transferability of conclusions of RCTs to usual care …

We performed a meta-analysis to compare the impact of triple combination therapy with
inhaled corticosteroids (ICS), long-acting β2-agonists (LABAs) and long-acting muscarinic …

Triple therapy for COPD consists of a long-acting anti-cholinergic bronchodilator, a long-
acting beta-agonist bronchodilator, and an inhaled corticosteroid. Guidelines from the …

A growing body of evidence suggests that triple therapy with an antimuscarinic agent, a long-
acting β2-agonist, and an inhaled corticosteroid is efficacious in patients with more severe …

Purpose Randomized trials report that single-inhaler triple therapy is more effective than
dual bronchodilators at reducing exacerbations in patients with chronic obstructive …

Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …

Although pharmacological treatment of COPD is codified in different guidelines and strategy
documents, there is abundant evidence of discrepancy between what they suggest and what …

Triple inhaled therapy for chronic obstructive pulmonary disease (COPD) consists of an
inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic …

New guidelines emphasize combination bronchodilators as a mainstay of therapy for many
patients with symptomatic COPD and there are several new combination bronchodilator …